Twist Bioscience IPO Hauls In $70M for DNA Synthesis Technology

Synthetic biology company Twist Bioscience has joined the long list of life science firms going public this year, raising $70 million in its stock market debut.

The San Francisco company sold 5 million shares at $14 apiece, which was within the $14 to $16 per share range it had targeted. After those shares started trading Wednesday morning, Twist’s (NASDAQ: TWST) stock price dipped more than 8 percent morning to $12.80 per share.